Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects
Publication
, Conference
Hillson, J; Mant, T; Ganguly, T; Avery, W; Rosano, M; Huntenburg, C; Palmer, D; Darne, S; Pavlova, B; Doralt, J; Reeve, R; Goel, N; Rhyne, P ...
Published in: ARTHRITIS & RHEUMATOLOGY
October 1, 2016
Duke Scholars
Published In
ARTHRITIS & RHEUMATOLOGY
EISSN
2326-5205
ISSN
2326-5191
Publication Date
October 1, 2016
Volume
68
Publisher
WILEY
Related Subject Headings
- 3204 Immunology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hillson, J., Mant, T., Ganguly, T., Avery, W., Rosano, M., Huntenburg, C., … Roach, J. (2016). Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects. In ARTHRITIS & RHEUMATOLOGY (Vol. 68). WILEY.
Hillson, Jan, Tim Mant, Tanmoy Ganguly, William Avery, Molly Rosano, Carolyn Huntenburg, Donna Palmer, et al. “Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects.” In ARTHRITIS & RHEUMATOLOGY, Vol. 68. WILEY, 2016.
Hillson J, Mant T, Ganguly T, Avery W, Rosano M, Huntenburg C, et al. Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects. In: ARTHRITIS & RHEUMATOLOGY. WILEY; 2016.
Hillson, Jan, et al. “Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects.” ARTHRITIS & RHEUMATOLOGY, vol. 68, WILEY, 2016.
Hillson J, Mant T, Ganguly T, Avery W, Rosano M, Huntenburg C, Palmer D, Darne S, Pavlova B, Doralt J, Reeve R, Goel N, Weilert D, Rhyne P, Caminis J, Roach J. Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA (R)), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects. ARTHRITIS & RHEUMATOLOGY. WILEY; 2016.
Published In
ARTHRITIS & RHEUMATOLOGY
EISSN
2326-5205
ISSN
2326-5191
Publication Date
October 1, 2016
Volume
68
Publisher
WILEY
Related Subject Headings
- 3204 Immunology
- 3202 Clinical sciences